University of Crete (UOC)
Αποτελέσματα και τοξικότητες της προληπτικής θεραπείας έναντι του κυτταρομεγαλοϊού (CMV) στις 100 πρώτες ημέρες μετά από Αλλογενή Μεταμόσχευση Μυελού των Οστών
Abstract
dc:descriptionBackground: Cytomegalovirus (CMV) remains the most common, clinically significant viral infection after allogeneic hematopoietic stem cell transplantation. Pre-emptive therapy (PET) with common antivirals, i.e. (val)ganciclovir and foscarnet, has been the preferred approach against the CMV infection over the past decades. Overarching aim: To evaluate the incidence of toxicity and clinical outcomes from the use of PET as well as evaluate the mortality outcomes at 1-year post-HCT in the letermovir era, using real-world data from a large tertiary cancer center. Methods: We included data from the analysis of 3 different cohorts: cohort 1 (368 patients): evaluation of toxicity and healthcare utilization use; cohort 2 (286 patients): evaluation of refractory/resistant CMV infection; cohort 3 (848 patients): evaluation of 1-year mortality among recipients of prophylactic letermovir and patients treated pre-emptively. Results: From the multivariate models, the use of PET was associated with increased risk of neutropenia (1.8x times, P < 0.0001) and acute kidney injury (2.75x, P <0.0001). PET was associated with significantly higher healthcare resource utilization and incremental cost of treatment. From cohort 2, 31.6% of patients treated pre-emptively developed clinical refractory CMV infection, defined as a non-responsive CMV viral load after at least 14 days of treatment. Though, only 6 out of the 46 patients with refractory infection had genotypically confirmed resistance mutation(s). Last, letermovir prophylaxis decreased common antiviral use by 88%, and was associated with improved 1-year survival. Comparing with the R-D- population, letermovir recipients had similar 1-year mortality (aHR, 0.89, 95% CI 0.57 – 1.41), while patients managed pre-emptively had higher mortality (aHR, 1.4, 95% CI 1.0.1 – 1.93). This observation was mainly driven by the TCD population (37.3% of cohort 3; aHR for death, 0.21, 95% CI 0.07 – 0.65), and was not statistically significant for the patients receiving conventional grafts. Conclusions: PET, although efficacious in preventing development of CMV end-organ disease, is associated with high levels of toxicity and healthcare resource utilization. Refractory infection is associated with dismal clinical outcomes. The use of newer antivirals, such as prophylaxis with letermovir, is generally better tolerated, can dramatically decrease the use of PET and might have a positive impact on survival, in, at least some, high-risk patient subgroups.
Degree
thesis:*- Grantor dc:publisher
- University of Crete (UOC)
- Year dc:date
- 2026
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Zavras, Phaedon-Dimitrios
- Ζάβρας, Φαίδων-Δημήτριος
Subjects
dc:subject × 12Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/61973